Drug Profile
AKS 301
Alternative Names: AKS-301Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Akston Biosciences
- Class Antineoplastics
- Mechanism of Action Glucose modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Cancer in USA
- 17 Aug 2017 Preclinical trials in Cancer in USA before August 2017 (Akston Biosciences pipeline, August 2017)